
Digital Diagnostics is a pioneering AI diagnostic healthcare technology company that focuses on transforming healthcare quality, accessibility, and affordability worldwide. The company is known for its Luminetics Core™ product, which is the first FDA-cleared AI diagnostic platform that can diagnose diabetic retinopathy without physician input. This innovative approach enhances patient access to specialty services in primary care settings, expedites referrals, and helps prevent vision loss through early detection. Digital Diagnostics has established itself as a leader in the market by emphasizing ethical AI practices and has garnered significant traction with numerous healthcare providers adopting its technology to improve patient outcomes.

Digital Diagnostics is a pioneering AI diagnostic healthcare technology company that focuses on transforming healthcare quality, accessibility, and affordability worldwide. The company is known for its Luminetics Core™ product, which is the first FDA-cleared AI diagnostic platform that can diagnose diabetic retinopathy without physician input. This innovative approach enhances patient access to specialty services in primary care settings, expedites referrals, and helps prevent vision loss through early detection. Digital Diagnostics has established itself as a leader in the market by emphasizing ethical AI practices and has garnered significant traction with numerous healthcare providers adopting its technology to improve patient outcomes.
Product: LumineticsCore — FDA-cleared autonomous AI diagnostic platform for diabetic retinopathy
Founded: 2010
Headquarters: Coralville, Iowa
Latest disclosed raise: $75M Series B (Aug 23, 2022)
Total funding (reported): $130M–$173.4M reported
Automated medical image analysis and autonomous AI diagnostics for diabetic retinopathy
2010
Healthcare technology / Medical AI
$75,000,000
Series B announced Aug 23, 2022 with participation from investors including Optum Ventures and 8VC
“KKR led Series B with participation from strategic health and venture investors including Optum Ventures and 8VC”